ENANTA PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
ENTA$11.22-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders' Equity
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balances, September 30, 2023 | 21,059 | $211 | $424,693 | $(1,174) | $(206,995) | $216,735 |
| Vesting of restricted stock units, net of withholding | 97 | 1 | (184) | — | — | (183) |
| Stock-based compensation expense | — | — | 8,099 | — | — | 8,099 |
| Other comprehensive income | — | — | — | 640 | — | 640 |
| Net loss | — | — | — | — | (33,407) | (33,407) |
| Balances, December 31, 2023 | 21,156 | $212 | $432,608 | $(534) | $(240,402) | $191,884 |
| Exercise of stock options | 6 | — | 51 | — | — | $51 |
| Vesting of restricted stock units, net of withholding | 17 | — | (92) | — | — | (92) |
| Stock-based compensation expense | — | — | 5,561 | — | — | 5,561 |
| Other comprehensive loss | — | — | — | (133) | — | (133) |
| Net loss | — | — | — | — | (31,157) | (31,157) |
| Balances, March 31, 2024 | 21,179 | $212 | $438,128 | $(667) | $(271,559) | $166,114 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balances, September 30, 2022 | 20,791 | $208 | $398,029 | $(3,724) | $(73,179) | $321,334 |
| Exercise of stock options | 56 | 1 | 1,125 | — | — | 1,126 |
| Vesting of restricted stock units, net of withholding | 37 | — | (825) | — | — | (825) |
| Stock-based compensation expense | — | — | 7,139 | — | — | 7,139 |
| Other comprehensive income | — | — | — | 1,049 | — | 1,049 |
| Net loss | — | — | — | — | (28,986) | (28,986) |
| Balances, December 31, 2022 | 20,884 | $209 | $405,468 | $(2,675) | $(102,165) | $300,837 |
| Exercise of stock options | 61 | 1 | 881 | — | — | 882 |
| Vesting of restricted stock units, net of withholding | 104 | — | (2,909) | — | — | (2,909) |
| Stock-based compensation expense | — | — | 7,363 | — | — | 7,363 |
| Other comprehensive income | — | — | — | 860 | — | 860 |
| Net loss | — | — | — | — | (37,658) | (37,658) |
| Balances at March 31, 2023 | 21,049 | $210 | $410,803 | $(1,815) | $(139,823) | $269,375 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.